Form 8-K

8-K — CLARIVATE PLC

Accession: 0001764046-26-000090

Filed: 2026-07-29

Period: 2026-07-29

CIK: 0001764046

SIC: 7374 (SERVICES-COMPUTER PROCESSING & DATA PREPARATION)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — clvt-20260729.htm (Primary)

EX-99.1 (ex991q22026earningsrelease.htm)

EX-99.2 (ex992q22026supplementald.htm)

GRAPHIC (ex992q22026supplementald001.jpg)

GRAPHIC (ex992q22026supplementald002.jpg)

GRAPHIC (ex992q22026supplementald003.jpg)

GRAPHIC (ex992q22026supplementald004.jpg)

GRAPHIC (ex992q22026supplementald005.jpg)

GRAPHIC (ex992q22026supplementald006.jpg)

GRAPHIC (ex992q22026supplementald007.jpg)

GRAPHIC (ex992q22026supplementald008.jpg)

GRAPHIC (ex992q22026supplementald009.jpg)

GRAPHIC (ex992q22026supplementald010.jpg)

GRAPHIC (ex992q22026supplementald011.jpg)

GRAPHIC (ex992q22026supplementald012.jpg)

GRAPHIC (ex992q22026supplementald013.jpg)

GRAPHIC (ex992q22026supplementald014.jpg)

GRAPHIC (ex992q22026supplementald015.jpg)

GRAPHIC (ex992q22026supplementald016.jpg)

GRAPHIC (ex992q22026supplementald017.jpg)

GRAPHIC (ex992q22026supplementald018.jpg)

GRAPHIC (ex992q22026supplementald019.jpg)

GRAPHIC (ex992q22026supplementald020.jpg)

GRAPHIC (ex992q22026supplementald021.jpg)

GRAPHIC (ex992q22026supplementald022.jpg)

GRAPHIC (ex992q22026supplementald023.jpg)

GRAPHIC (ex992q22026supplementald024.jpg)

GRAPHIC (ex992q22026supplementald025.jpg)

GRAPHIC (ex992q22026supplementald026.jpg)

GRAPHIC (ex992q22026supplementald027.jpg)

GRAPHIC (ex992q22026supplementald028.jpg)

GRAPHIC (ex992q22026supplementald029.jpg)

GRAPHIC (ex992q22026supplementald030.jpg)

GRAPHIC (ex992q22026supplementald031.jpg)

GRAPHIC (ex992q22026supplementald032.jpg)

GRAPHIC (ex992q22026supplementald033.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: clvt-20260729.htm · Sequence: 1

clvt-20260729

0001764046false00-000000000017640462026-07-292026-07-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

July 29, 2026

Date of Report (date of earliest event reported)

CLARIVATE PLC

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands

(State or other jurisdiction of incorporation or organization)

001-38911

(Commission File Number)

N/A

(I.R.S. Employer Identification No.)

70 St. Mary Axe

London

EC3A 8BE

United Kingdom

(Address of Principal Executive Offices)

(44) 207-433-4000

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant

under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Ordinary Shares, no par value

CLVT

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933

(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On July 29, 2026, Clarivate Plc (the “Company”) issued a press release announcing earnings for the second quarter ended June

30, 2026. The press release has been furnished with this Form 8-K as Exhibit 99.1 and is posted on the investor relations section

of the Company’s website (ir.clarivate.com/).

The information in this Item 2.02, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed”

for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject

to the liabilities of that Section and shall not be incorporated by reference into any filing pursuant to the Securities Act of 1933,

as amended (the “Securities Act”), or the Exchange Act, except as otherwise expressly stated in such filing.

Item 7.01. Regulation FD Disclosure.

On July 29, 2026, the Company posted to its website supplemental information related to revenue, earnings, and guidance. The

supplemental information has been furnished with this Current Report on Form 8-K as Exhibit 99.2 and is posted on the

investor relations section of the Company’s website (ir.clarivate.com/).

The information in this Item 7.01, including Exhibit 99.2 furnished herewith, is being furnished and shall not be deemed “filed”

for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section and shall not be

incorporated by reference into any filing pursuant to the Securities Act or the Exchange Act, except as otherwise expressly

stated in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

No.

Description

99.1

Press release issued by Clarivate Plc dated July 29, 2026

99.2

Supplemental Information dated July 29, 2026

104

The cover page from the Company's Current Report on Form 8-K dated July 29, 2026, formatted in Inline XBRL

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on

its behalf by the undersigned hereunto duly authorized.

CLARIVATE PLC

Date: July 29, 2026

By: /s/ Jonathan M. Collins

Name: Jonathan M. Collins

Executive Vice President & Chief Financial Officer

EX-99.1

Filename: ex991q22026earningsrelease.htm · Sequence: 2

Ex. 99.1 Q2 2026 Earnings Release

Clarivate Reports Second Quarter 2026 Results

— Delivers continued progress on strategic and financial priorities through Value Creation Plan —

— Sharpens focus and enhances financial profile with previously announced Life Sciences &

Healthcare segment divestiture —

— Reaffirms 2026 financial outlook —

London, UK -- July 29, 2026 Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a leading global

provider of transformative intelligence, today reported results for the second quarter ended June 30, 2026.

Executive Commentary

Matti Shem Tov, Chief Executive Officer:

“The Value Creation Plan continues to drive meaningful progress, as we execute against our strategic priorities

and strengthen Clarivate’s foundation for organic growth acceleration. During the quarter, we expanded organic

recurring revenue, advanced our AI innovation roadmap, maintained disciplined cost management, and

strengthened our balance sheet through deleveraging. Together, with the recently announced divestiture of the

Life Sciences & Healthcare segment, these actions are creating a more focused company with greater financial

flexibility, a higher recurring revenue mix, and a clear path to deliver long-term value to shareholders.”

Jonathan Collins, Executive Vice President and Chief Financial Officer:

“Our second quarter results reflect continued financial discipline and execution. In the first half of 2026, we

expanded our profit margin and reduced debt by more than $200 million through strong free cash flow generation

and opportunistic debt repurchases. Combined with our reaffirmed full-year outlook, these results demonstrate the

resilience of our business model and our commitment to strengthening Clarivate’s financial profile while

maintaining the flexibility to invest in our highest-value growth opportunities.”

Second Quarter 2026 Results

Total revenues were $587.3 million, compared to total revenues of $621.4 million for the second quarter of 2025,

primarily due to inorganic divestitures and disposals. Organic revenues decreased 1.5% as organic subscription

growth of 0.7% was offset by lower organic transactional revenues.

Organic ACV grew 1.5% compared to June 30, 2025, reflecting continued progress toward a more sustainable,

subscription-led revenue base.

Net loss was $268.6 million, or $0.42 per diluted share, compared to a net loss of $72.0 million, or $0.11 per

diluted share, for the second quarter of 2025, driven by a $221.7 million non-cash goodwill impairment charge.

Adjusted net income was $123.1 million, or $0.19 per diluted share, compared to $123.3 million, or $0.18 per

diluted share, for the second quarter of 2025. Adjusted EBITDA was $247.2 million, compared to Adjusted

EBITDA of $261.6 million for the second quarter of 2025.

First Half 2026 Results

Total revenues were $1,172.8 million, compared to total revenues of $1,215.1 million for the first six months of

2025, primarily due to inorganic divestitures and disposals. Organic revenues decreased 0.4%, as a 0.7% increase

in organic recurring revenues (subscription and re-occurring) was offset by lower organic transactional revenues.

Net loss was $308.8 million, or $0.48 per diluted share, compared to a net loss of $175.9 million, or $0.26 per

diluted share, for the first six months of 2025, driven by a $221.7 million non-cash goodwill impairment charge in

the second quarter of 2026. Adjusted net income was $242.4 million, or $0.38 per diluted share, compared to

$219.1 million, or $0.32 per diluted share, for the first six months of 2025. Adjusted EBITDA was $488.4 million,

compared to Adjusted EBITDA of $494.8 million for the first six months of 2025.

Clarivate generated $233.4 million of operating cash flow and $122.9 million of free cash flow during the first six

months of 2026.

Selected Financial Information

(In millions, except percentages and per share data),

(unaudited)

Three Months Ended

June 30,

Change

Six Months Ended

June 30,

Change

2026

2025

2026

2025

Revenues

$587.3

$621.4

$(34.1)

(5.5)%

$1,172.8

$1,215.1

$(42.3)

(3.5)%

Net income (loss)

$(268.6)

$(72.0)

$(196.6)

N/M

$(308.8)

$(175.9)

$(132.9)

(75.6)%

Adjusted net income(1)

$123.1

$123.3

$(0.2)

(0.2)%

$242.4

$219.1

$23.3

10.6%

Adjusted EBITDA(1)

$247.2

$261.6

$(14.4)

(5.5)%

$488.4

$494.8

$(6.4)

(1.3)%

Diluted EPS

$(0.42)

$(0.11)

$(0.31)

N/M

$(0.48)

$(0.26)

$(0.22)

(84.6)%

Adjusted diluted EPS(1)

$0.19

$0.18

$0.01

5.6%

$0.38

$0.32

$0.06

18.8%

Net cash provided by operating activities

$98.7

$116.3

$(17.6)

(15.1)%

$233.4

$287.5

$(54.1)

(18.8)%

Free cash flow(1)

$44.0

$50.3

$(6.3)

(12.5)%

$122.9

$160.6

$(37.7)

(23.5)%

Second Quarter 2026 Commentary

Subscription revenues decreased $2.4 million, or 0.6%, to $403.3 million, primarily due to product group wind-

downs within LS&H. Organic subscription revenues increased 0.7%, primarily due to new sales and price

increases.

Re-occurring revenues increased $0.4 million, or 0.4%, to $109.3 million, primarily due to foreign exchange

benefit.

Recurring revenues, which consist of subscription and re-occurring revenues, increased 0.5% organically.

Transactional revenues decreased $32.1 million, or 30.1%, to $74.7 million, primarily due to product group wind-

downs within A&G. Organic transactional revenues decreased 15.7%, primarily due to lower activity across all

segments, driven in part by customer migrations to subscription offerings.

Balance Sheet and Cash Flow

As of June 30, 2026, cash and cash equivalents of $217.7 million decreased $111.5 million compared to

December 31, 2025.

Total debt outstanding was $4,251.5 million as of June 30, 2026, a decrease of $218.4 million compared to the

prior year, driven by a $100.0 million accelerated debt repayment completed in January 2026, fully redeeming the

senior secured notes due November 2026, as well as the retirement of $117.6 million aggregate principal of the

senior secured notes due 2028 and senior notes due 2029 through a series of debt repurchases at an approximate

6% discount to par.

Net cash provided by operating activities for the first six months of 2026 was $233.4 million compared to $287.5

million in the prior year period. Free cash flow for the first six months of 2026 was $122.9 million compared to

$160.6 million in the prior year period.

Reaffirms outlook for 2026 (forward-looking statement)

The full year outlook presented below assumes no further acquisitions, divestitures, or unanticipated events.

Full Year 2026 Outlook

ACV Organic Growth

2.0% to 3.0%

Recurring Organic Revenue Growth

0.75% to 2.25%

Revenues, Including Discontinued Operations(1)

$2.30B to $2.42B

Adjusted EBITDA(1)

$980M to $1.04B

Adjusted EBITDA Margin(1)

42.0% to 43.5%

Adjusted Diluted EPS(1)(2)

$0.70 to $0.80

Free Cash Flow(1)

$365M to $435M

Notes to press release

(1) Non-GAAP measure. Please see “Reconciliations to Certain Non-GAAP Measures” in this release for important disclosures and reconciliations of these

financial measures to the most directly comparable GAAP measure. These terms are defined elsewhere in this press release.

(2) Adjusted diluted EPS for 2026 is calculated based on approximately 650 million fully diluted adjusted weighted average ordinary shares outstanding.

Conference Call and Webcast

Clarivate will host a conference call and webcast today to review the results for the second quarter at 9:30 a.m.

Eastern Time. The webcast is open to all interested parties and may include forward-looking information.

The live webcast of the earnings call will be accessible through the investor relations section of the Company’s

website. To join the webcast please visit https://events.q4inc.com/attendee/248169870.

Interested parties may access the live audio broadcast. U.S. participants may call 833-461-5787; international

participants may call +1 585-542-9983 (long-distance charges will apply). The conference ID number is

248169870.

A replay of the webcast will also be available on https://ir.clarivate.com beginning two hours after the conclusion

of the live call and will remain available for one year.

Use of Non-GAAP Financial Measures

This release contains financial measures that have not been prepared in accordance with U.S. generally accepted

accounting principles (“GAAP”), including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted net income,

Adjusted diluted EPS, Free cash flow, and Revenues, including discontinued operations. Non-GAAP financial

measures are not recognized terms under GAAP, are not measures of financial condition or liquidity, and should

not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or

operating cash flows determined in accordance with GAAP. As a result, you should not consider such measures in

isolation from, or as a substitute for, financial measures or results of operations calculated or determined in

accordance with GAAP.

We use non-GAAP measures internally in our operational and financial decision-making, to assess the operating

performance of our business, to assess performance for employee compensation purposes, and to decide how to

allocate resources. We believe that such measures allow us to focus on what we deem to be more reliable

indicators of ongoing operating performance and our ability to generate cash flow from operations, and we also

believe that investors may find these non-GAAP financial measures useful for the same reasons. Non-GAAP

measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of

companies comparable to us, many of which present non-GAAP measures when reporting their results. Further,

these measures can be useful in evaluating our performance against our peer companies because we believe they

provide users with valuable insight into key components of our GAAP financial disclosure. However, non-GAAP

measures have limitations as analytical tools and because not all companies use identical calculations, our

presentation of non-GAAP financial measures may not be comparable to other similarly titled measures of other

companies.

Definitions and reconciliations of non-GAAP measures to the most directly comparable GAAP measures are

provided within the schedules attached to this release. Our presentation of non-GAAP measures should not be

construed as an inference that our future results will be unaffected by any of the adjusted items, or that any

projections and estimates will be realized in their entirety or at all.

Forward-Looking Statements

This release includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or

projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking

statements” within the meaning of the “safe harbor provisions” of the Private Securities Litigation Reform Act of

1995. These forward-looking statements include all matters that are not historical facts, including statements

relating to our intentions, beliefs, or current expectations concerning, among other things, the divestiture of our

Life Sciences & Healthcare business or any other strategic transactions we may explore, the anticipated use of

proceeds from the divestiture of our Life Sciences & Healthcare business, anticipated cost savings or other

benefits, results of operations, financial condition, liquidity, capital allocation plans and share repurchases, foreign

exchange impacts, prospects, growth and shareholder value, strategies, and the markets in which we operate, our

financial guidance for the fiscal year 2026 and key drivers thereof and underlying assumptions, the impact or

anticipated benefits of our Value Creation Plan and other growth strategies, the global macroeconomic uncertainty

and volatility, the impact of artificial intelligence (“AI”) on our business and strategy, and the timing of any of the

foregoing. These forward-looking statements can generally be identified by the use of forward-looking

terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “seeks,” “projects,” “intends,”

“plans,” “may,” “will,” or “should” or, in each case, their negative or other variations or comparable terminology.

Such forward-looking statements are based on available current market material and management’s expectations,

beliefs, and forecasts concerning future events impacting us. These forward-looking statements involve a number

of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual

results or performance to be materially different from those expressed or implied by these forward-looking

statements. These risks and uncertainties include, but are not limited to, those factors described in Item 1A. Risk

Factors in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange

Commission (“SEC”). There can be no assurance that future developments affecting us will be those that we have

anticipated. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove

incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of

new information, future events, or otherwise, except as may be required under applicable securities laws. Please

consult our public filings with the SEC, which are also available on our website at www.clarivate.com.

About Clarivate

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics,

workflow solutions and expert services in the areas of Academia & Government, Intellectual Property, and Life

Sciences & Healthcare. For more information, please visit www.clarivate.com.

Condensed Consolidated Balance Sheets – Unaudited

(In millions)

June 30, 2026

December 31, 2025

ASSETS

Current assets:

Cash and cash equivalents, including restricted cash

$217.7

$329.2

Accounts receivable, net

827.9

821.7

Prepaid expenses

107.1

94.2

Other current assets

61.5

64.9

Total current assets

1,214.2

1,310.0

Property and equipment, net

49.5

52.7

Other intangible assets, net

7,734.3

8,008.1

Goodwill

1,344.9

1,566.7

Other non-current assets

86.5

68.1

Deferred income taxes

17.9

17.2

Operating lease right-of-use assets

38.8

46.6

Total assets

$10,486.1

$11,069.4

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:

Accounts payable

$152.9

$150.6

Accrued compensation

99.0

146.7

Accrued expenses and other current liabilities

268.5

273.0

Current portion of deferred revenues

897.0

878.6

Current portion of operating lease liability

16.7

18.4

Current portion of long-term debt

1.6

101.5

Total current liabilities

1,435.7

1,568.8

Long-term debt

4,209.3

4,321.5

Other non-current liabilities

75.8

86.2

Deferred income taxes

197.9

212.1

Operating lease liabilities

29.9

37.9

Total liabilities

5,948.6

6,226.5

Commitments and contingencies

Shareholders' equity:

Ordinary Shares, no par value; unlimited shares authorized; 639.7 and 640.7 shares issued and

outstanding as of June 30, 2026 and December 31, 2025, respectively

12,815.2

12,810.6

Accumulated other comprehensive loss

(454.3)

(453.1)

Accumulated deficit

(7,823.4)

(7,514.6)

Total shareholders' equity

4,537.5

4,842.9

Total liabilities and shareholders' equity

$10,486.1

$11,069.4

Condensed Consolidated Statements of Operations – Unaudited

Three Months Ended June 30,

Six Months Ended June 30,

(In millions, except per share data)

2026

2025

2026

2025

Revenues

$587.3

$621.4

$1,172.8

$1,215.1

Operating expenses:

Cost of revenues

185.5

203.6

377.6

410.6

Selling, general and administrative costs

181.6

181.1

357.9

359.5

Depreciation and amortization

185.7

190.9

369.7

376.3

Goodwill and intangible asset impairments

221.7

–

221.7

–

Restructuring costs

12.1

9.3

24.1

34.0

Other operating expense (income), net

0.9

29.6

(8.2)

48.6

Total operating expenses

787.5

614.5

1,342.8

1,229.0

Income (loss) from operations

(200.2)

6.9

(170.0)

(13.9)

Interest expense, net

60.4

66.6

119.4

130.9

Income (loss) before income taxes

(260.6)

(59.7)

(289.4)

(144.8)

Provision (benefit) for income taxes

8.0

12.3

19.4

31.1

Net income (loss)

$(268.6)

$(72.0)

$(308.8)

$(175.9)

Per share:

Basic

$(0.42)

$(0.11)

$(0.48)

$(0.26)

Diluted

$(0.42)

$(0.11)

$(0.48)

$(0.26)

Weighted average shares used to compute earnings per share:

Basic

639.4

681.3

640.0

685.5

Diluted

639.4

681.3

640.0

685.5

Condensed Consolidated Statements of Cash Flows – Unaudited

Six Months Ended June 30,

(In millions)

2026

2025

Cash Flows From Operating Activities

Net income (loss)

$(308.8)

$(175.9)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

Depreciation and amortization

369.7

376.3

Share-based compensation

29.4

29.3

Goodwill and intangible asset impairments

221.7

–

Deferred income taxes

(11.3)

(5.4)

Amortization and write-off of debt issuance costs

6.6

7.7

Other operating activities

(14.0)

48.0

Changes in operating assets and liabilities:

Accounts receivable

(11.3)

2.2

Prepaid expenses

(13.3)

(1.5)

Other assets

(5.0)

3.1

Accounts payable

3.2

(3.3)

Accrued expenses and other current liabilities

(54.3)

(36.1)

Deferred revenues

24.4

42.6

Operating leases, net

(1.9)

(3.2)

Other liabilities

(1.7)

3.7

Net cash provided by operating activities

233.4

287.5

Cash Flows From Investing Activities

Capital expenditures

(110.5)

(126.9)

Net cash used for investing activities

(110.5)

(126.9)

Cash Flows From Financing Activities

Principal payments on debt

(211.1)

(500.0)

Proceeds from issuance of debt

–

500.0

Payment of debt issuance and extinguishment costs

–

(8.5)

Repurchases of ordinary shares

(18.1)

(99.5)

Payments related to tax withholding for share-based compensation

(6.6)

(8.1)

Other financing activities

4.6

5.6

Net cash used for financing activities

(231.2)

(110.5)

Effects of exchange rates

(3.2)

17.3

Net change in cash and cash equivalents, including restricted cash

(111.5)

67.4

Cash and cash equivalents, including restricted cash, beginning of period

329.2

295.2

Cash and cash equivalents, including restricted cash, end of period

$217.7

$362.6

Supplemental Revenues Information

Annualized contract value (“ACV”), at any point in time, represents the annualized value of all active customer

subscription-based license agreements for the next 12 months, assuming those coming up for renewal during the

measurement period are renewed at their current price level. Our organic ACV grew 1.5% compared to June 30,

2025, primarily driven by improved product pricing. Our total ACV for June 30, 2026, compared to June 30,

2025, increased 3.1%, primarily due to improved product pricing and FX movements.

The following tables present our revenues by type and segment, as well as the components driving the changes

between periods.

Revenues by transaction type

(In millions, except percentages);

(unaudited)

Three Months Ended

June 30,

Change

% of Change

2026

2025

Acquisitions

Disposals

Organic

Subscription

$403.3

$405.7

$(2.4)

(0.6)%

—%

(1.0)%

(0.3)%

0.7%

Re-occurring

109.3

108.9

0.4

0.4%

—%

0.4%

—%

Recurring revenues

512.6

514.6

(2.0)

(0.4)%

—%

(0.7)%

(0.2)%

0.5%

Transactional

74.7

106.8

(32.1)

(30.1)%

—%

(14.1)%

(0.3)%

(15.7)%

Revenues

$587.3

$621.4

$(34.1)

(5.5)%

—%

(3.8)%

(0.2)%

(1.5)%

(In millions, except percentages);

(unaudited)

Six Months Ended

June 30,

Change

% of Change

2026

2025

Acquisitions

Disposals

Organic

Subscription

$800.8

$794.3

$6.5

0.8%

—%

(1.2)%

0.8%

1.2%

Re-occurring

217.9

214.8

3.1

1.4%

—%

(0.1)%

2.3%

(0.8)%

Recurring revenues

1,018.7

1,009.1

9.6

1.0%

—%

(0.8)%

1.1%

0.7%

Transactional

154.1

206.0

(51.9)

(25.2)%

—%

(16.3)%

0.5%

(9.4)%

Revenues

$1,172.8

$1,215.1

$(42.3)

(3.5)%

—%

(4.1)%

1.0%

(0.4)%

Revenues by segment

(In millions, except percentages);

(unaudited)

Three Months Ended

June 30,

Change

% of Change

2026

2025

Acquisitions

Disposals

Organic

Academia & Government

$300.3

$318.5

$(18.2)

(5.7)%

—%

(5.9)%

(0.1)%

0.3%

Intellectual Property

198.3

202.5

(4.2)

(2.1)%

—%

0.2%

(2.3)%

Life Sciences & Healthcare

88.7

100.4

(11.7)

(11.7)%

—%

(5.4)%

(1.1)%

(5.2)%

Revenues

$587.3

$621.4

$(34.1)

(5.5)%

—%

(3.8)%

(0.2)%

(1.5)%

(In millions, except percentages);

(unaudited)

Six Months Ended

June 30,

Change

% of Change

2026

2025

Acquisitions

Disposals

Organic

Academia & Government

$595.3

$621.2

$(25.9)

(4.2)%

—%

(6.1)%

0.7%

1.2%

Intellectual Property

395.5

395.2

0.3

0.1%

—%

1.9%

(1.8)%

Life Sciences & Healthcare

182.0

198.7

(16.7)

(8.4)%

—%

(6.0)%

(0.1)%

(2.3)%

Revenues

$1,172.8

$1,215.1

$(42.3)

(3.5)%

—%

(4.1)%

1.0%

(0.4)%

Reconciliations to Certain Non-GAAP Measures

Adjusted EBITDA and Adjusted EBITDA margin

Adjusted EBITDA represents Net income (loss) before the Provision (benefit) for income taxes, Depreciation and

amortization, and Interest expense, net, adjusted to exclude share-based compensation, impairments, restructuring

expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or

disposal-related transaction costs, unrealized foreign currency gains/losses, legal settlements, and other items that

are included in Net income (loss) for the period that we do not consider indicative of our ongoing operating

performance. Net income (loss) margin is calculated by dividing Net income (loss) by Revenues. Adjusted

EBITDA margin is calculated by dividing Adjusted EBITDA by Revenues.

The following table presents our calculation of Adjusted EBITDA and Adjusted EBITDA margin for the three

and six months ended June 30, 2026 and 2025 and reconciles these non-GAAP measures to our Net income (loss)

and Net income (loss) margin for the same periods:

Three Months Ended June 30,

Six Months Ended June 30,

(In millions, except percentages); (unaudited)

2026

2025

2026

2025

Net income (loss)

$(268.6)

$(72.0)

$(308.8)

$(175.9)

Provision (benefit) for income taxes

8.0

12.3

19.4

31.1

Depreciation and amortization

185.7

190.9

369.7

376.3

Interest expense, net

60.4

66.6

119.4

130.9

Share-based compensation expense

15.1

18.5

29.7

29.6

Goodwill and intangible asset impairments

221.7

—

221.7

—

Restructuring costs

12.1

9.3

24.1

34.0

Transaction related costs

10.2

8.1

18.4

14.4

Other(1)

2.6

27.9

(5.2)

54.4

Adjusted EBITDA

$247.2

$261.6

$488.4

$494.8

Net income (loss) margin

(45.7)%

(11.6)%

(26.3)%

(14.5)%

Adjusted EBITDA margin

42.1%

41.6%

40.7%

(1)Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing

operating performance.

Adjusted net income and Adjusted diluted EPS

Adjusted net income represents Net income (loss), adjusted to exclude amortization related to acquired intangible

assets, share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value

adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign

currency gains/losses, legal settlements, and other items that are included in net income (loss) for the period that

we do not consider indicative of our ongoing operating performance and the associated income tax impact of such

adjustments.

Adjusted diluted EPS is calculated by dividing Adjusted net income by Adjusted diluted weighted average shares.

The Adjusted diluted weighted average shares calculation assumes that all instruments in the calculation are

dilutive.

The following tables present our calculation of Adjusted net income and Adjusted diluted EPS for the three and

six months ended June 30, 2026 and 2025 and reconciles these non-GAAP measures to our Net income (loss) and

diluted EPS for the same periods:

Three Months Ended June 30,

2026

2025

(In millions, except per share amounts); (unaudited)

Amount

Per Share

Amount

Per Share

Net income (loss) and Diluted EPS

$(268.6)

$(0.42)

$(72.0)

$(0.11)

Amortization related to acquired intangible assets

135.3

0.21

137.0

0.20

Share-based compensation expense

15.1

0.02

18.5

0.03

Goodwill and intangible asset impairments

221.7

0.35

—

Restructuring costs

12.1

0.02

9.3

0.01

Transaction related costs

10.2

0.02

8.1

0.01

Other(1)

4.3

—

28.0

0.05

Income tax impact of related adjustments

(7.0)

(0.01)

(5.6)

(0.01)

Adjusted net income and Adjusted diluted EPS

$123.1

$0.19

$123.3

$0.18

Adjusted weighted average ordinary shares, diluted

642.7

684.6

(1)Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing

operating performance.

Six Months Ended June 30,

2026

2025

(In millions, except per share amounts); (unaudited)

Amount

Per Share

Amount

Per Share

Net income (loss) and Diluted EPS

$(308.8)

$(0.48)

$(175.9)

$(0.26)

Amortization related to acquired intangible assets

270.7

0.42

273.3

0.40

Share-based compensation expense

29.7

0.05

29.6

0.04

Goodwill and intangible asset impairments

221.7

0.35

—

Restructuring costs

24.1

0.04

34.0

0.05

Transaction related costs

18.4

0.03

14.4

0.02

Other(1)

(1.9)

(0.01)

54.5

0.09

Income tax impact of related adjustments

(11.5)

(0.02)

(10.8)

(0.02)

Adjusted net income and Adjusted diluted EPS

$242.4

$0.38

$219.1

$0.32

Adjusted weighted average ordinary shares, diluted

645.0

689.9

(1)Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing

operating performance.

Free cash flow

Free cash flow represents Net cash provided by operating activities less Capital expenditures. The following table

presents our calculation of Free cash flow for the three and six months ended June 30, 2026 and 2025 and

reconciles this non-GAAP measure to Net cash provided by operating activities for the same periods:

Three Months Ended June 30,

Six Months Ended June 30,

(In millions); (unaudited)

2026

2025

2026

2025

Net cash provided by operating activities

$98.7

$116.3

$233.4

$287.5

Capital expenditures

(54.7)

(66.0)

(110.5)

(126.9)

Free cash flow

$44.0

$50.3

$122.9

$160.6

Reconciliations to Certain Non-GAAP Measures - 2026 Outlook

Adjusted EBITDA and Adjusted EBITDA margin

The following table presents our calculation of Adjusted EBITDA and Adjusted EBITDA margin for the 2026

outlook and reconciles these non-GAAP measures to our Net income (loss) and Net income (loss) margin for the

same period:

Year Ending December 31, 2026

(Forecasted)

(In millions); (unaudited)

Low

High

Net income (loss)

$(418)

$(353)

Provision (benefit) for income taxes

Depreciation and amortization

760

Interest expense, net

242

237

Share-based compensation expense

Goodwill and intangible asset impairments

222

Restructuring costs(1)

Transaction related costs

Other

(11)

Adjusted EBITDA

$980

$1,040

Net income (loss) margin

(18.2)%

(14.6)%

Adjusted EBITDA margin

42.0%

43.5%

(1)Reflects restructuring costs expected to be incurred in 2026 associated with the Value Creation Plan.

Adjusted diluted EPS

The following table presents our calculation of Adjusted diluted EPS for the 2026 outlook and reconciles this non-

GAAP measure to our Net income (loss) per share for the same period:

Year Ending December 31, 2026

(Forecasted)

(Unaudited)

Low

High

Net income (loss) per share

$(0.64)

$(0.54)

Amortization related to acquired intangible assets

0.83

Share-based compensation expense

0.11

Goodwill and intangible asset impairments

0.34

Restructuring costs(1)

0.05

Transaction related costs

0.05

Other

(0.01)

Income tax impact of related adjustments

(0.03)

Adjusted diluted EPS

$0.70

$0.80

Adjusted weighted average ordinary shares, diluted

~650 million

(1)Reflects restructuring costs expected to be incurred in 2026 associated with the Value Creation Plan.

Free cash flow

The following table presents our calculation of Free cash flow for the 2026 outlook and reconciles this non-GAAP

measure to our Net cash provided by operating activities for the same period:

Year Ending December 31, 2026

(Forecasted)

(In millions); (unaudited)

Low

High

Net cash provided by operating activities

$610

$680

Capital expenditures

(245)

Free cash flow

$365

$435

Revenues, including discontinued operations

Revenues, including discontinued operations represents total company revenues including those attributable to

discontinued operations, which will begin to be reported in the third quarter for the LS&H segment.

The following table presents our calculation of Revenues, including discontinued operations and reconciles this

non-GAAP measure to our Revenues, excluding discontinued operations for the same period:

Year Ending December 31, 2026

(Forecasted)

(In millions); (unaudited)

Low

High

Revenues, including discontinued operations

$2,300

$2,420

Revenues attributable to discontinued operations

(360)

(380)

Revenues

$1,940

$2,040

Media Contact:

Amy Bourke-Waite, Senior Director, Communications & Brand

newsroom@clarivate.com

Investor Relations Contact:

Mark Donohue, Vice President, Investor Relations

investor.relations@clarivate.com

EX-99.2

Filename: ex992q22026supplementald.htm · Sequence: 3

ex992q22026supplementald

Q2 2026 Earnings Call July 29, 2026

Safe Harbor Statement and Non-GAAP Financial Measures © 2026 Clarivate. All rights reserved. 2 Forward-Looking Statements This presentation includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of the “safe harbor provisions” of the Private Securities Litigation Reform Act of 1995. Forward-looking statements included in this presentation include all matters that are not historical facts, including statements relating to our intentions, beliefs, or current expectations concerning, among other things, the divestiture of our LS&H business or any other strategic transactions we may explore, the anticipated use of proceeds from the divestiture of our Life Sciences & Healthcare business, anticipated cost savings or other benefits, results of operations, financial condition, liquidity, capital allocation plans and share repurchases, foreign exchange impacts, prospects, growth and shareholder value, strategies, and the markets in which we operate, our financial guidance for the fiscal year 2026 and key drivers thereof and underlying assumptions, the impact or anticipated benefits of our Value Creation Plan and other growth strategies, the global macroeconomic uncertainty and volatility, the impact of artificial intelligence (“AI”) on our business and strategy, and the timing of any of the foregoing. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “seeks,” “projects,” “intends,” “plans,” “may,” “will,” or “should” or, in each case, their negative or other variations or comparable terminology. Such forward-looking statements are based on available current market material and management's expectations, beliefs, and forecasts concerning future events impacting us. These forward- looking statements involve a number of risks, uncertainties, and other important factors (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Factors that may impact such forward-looking statements include, but are not limited to, our ability to compete in the highly competitive industry in which we operate; our ability to maintain high annual renewal rates; our ability to maintain revenues if our products and services do not achieve and maintain broad market acceptance, or if we are unable to keep pace with or adapt to rapidly changing technology, evolving industry standards, and changing regulatory requirements; reductions in customers’ research budgets or government funding; the success of our Value Creation Plan; our ability to derive fully the anticipated benefits from organic growth, existing or future acquisitions, joint ventures, investments, or dispositions; our exposure to risk from the international scope of our operations; our level of indebtedness; our ability to leverage AI in our products and services; any significant disruption in or unauthorized access to or breaches of our computer systems or those of third parties that we utilize in our operations; other factors beyond our control; and those factors described in Item 1A. Risk Factors in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). There can be no assurance that future developments affecting us will be those that we have anticipated. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws. Please consult our public filings with the SEC, which are also available on our website at www.clarivate.com.

Safe Harbor Statement and Non-GAAP Financial Measures © 2026 Clarivate. All rights reserved. 3 Non-GAAP Financial Measures This presentation contains financial measures that have not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Diluted EPS, Free Cash Flow, and Revenues, Including Discontinued Operations. Non-GAAP financial measures are not recognized terms under GAAP, are not measures of financial condition or liquidity, and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. As a result, you should not consider such measures in isolation from, or as a substitute for, financial measures or results of operations calculated or determined in accordance with GAAP. We use non-GAAP measures internally in our operational and financial decision-making, to assess the operating performance of our business, to assess performance for employee compensation purposes, and to decide how to allocate resources. We believe that such measures allow us to focus on what we deem to be more reliable indicators of ongoing operating performance and our ability to generate cash flow from operations, and we also believe that investors may find these non-GAAP financial measures useful for the same reasons. Non-GAAP measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures when reporting their results. Further, these measures can be useful in evaluating our performance against our peer companies because we believe they provide users with valuable insight into key components of our GAAP financial disclosure. However, non-GAAP measures have limitations as analytical tools and because not all companies use identical calculations, our presentation of non-GAAP financial measures may not be comparable to other similarly titled measures of other companies. Definitions and reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures are provided within the Appendix to this presentation. Our presentation of non-GAAP measures should not be construed as an inference that our future results will be unaffected by any of the adjusted items, or that any projections and estimates will be realized in their entirety or at all. Industry and Market Data The market data and other statistical information used throughout this presentation are based on industry publications and surveys, public filings, and various government sources. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of the included information. We have not independently verified such third-party information, nor have we ascertained the underlying economic assumptions relied upon in those sources, and we are unable to assure you of the accuracy or completeness of such information contained in this presentation. While we are not aware of any misstatements regarding our market, industry, or similar data presented herein, such data involve risks and uncertainties and are subject to change based on various factors.

Matti Shem Tov Chief Executive Officer Business Review

Q2 2026 Overview 6 ACV Organic Growth: 1.5% ▲ 20 bps YoY H1 Subs Organic Growth: 1.2% ▲ 60 bps YoY H1 Recurring Organic Growth: 0.7% 42.1% Margin1 ▲ 90 bps sequentially $75m debt reduction H1 debt reduction of $218m ▲ 1₵ YoY Revenues Adj. EBITDA¹ Free Cash Flow1 Adj. EPS1 $587M $247M $44M 19₵ Academia & Government Organic ACV and subs revenue growth at 2% Introduced Nexus Connect, the first scholarly institutional AI gateway to trusted research Intellectual Property Re-occurring organic revenue flat in Q2; expecting return to growth in H2 Introduced IPOne, a unified AI-native platform for patent and trademark agentic intelligence Life Sciences & Healthcare Organic ACV growth at 2% Reached definitive agreement to sell segment to Altaris LLC subsequent to Q22 1 See the Appendix for a reconciliation of GAAP to Non-GAAP measures. 2 Subject to customary regulatory approvals and closing conditions. © 2026 Clarivate. All rights reserved.

Value Creation Plan Driving Focus, Growth and Innovation Product & Agentic AI Accelerated Innovation Invest in proprietary assets and drive development of Agentic-AI capabilities across portfolio Optimize ROI and Support Sales Execution Sales Improved Sales Execution Drive sales execution, customer engagement and retention Increase Organic Growth and Achieve Targets Revenue Business Model Optimization Focus on driving core subscription and re-occurring revenue improving predictability Increase Subscription and Re-occurring Revenue Mix Portfolio Solutions Rationalization Assess strategic alternatives to increase execution focus and optimize capital allocation Unlock Value for Shareholders 7 Value Creation Enablers Talent and Culture Cost Rationalization Enterprise Technology © 2026 Clarivate. All rights reserved.

Scaling Academic AI as the Trusted Layer Between AI and Research © 2026 Clarivate. All rights reserved. 8 Academia & Government: Academic AI Web of Science Research Intelligence AI RESEARCH ASSISTANTS AND WORKFLOW AGENTS Launched Web of Science Research Intelligence Globally AI-native platform for research funding, strategy and impact, shaped by 50+ development partners and early adopters across 20 countries, grounding every insight in publisher-neutral Web of Science data with full provenance; generated multi-million-dollar ACV pipeline AI ECOSYSTEM ACCESS Introduced Nexus Connect, the AI Gateway to Scholarly Intelligence An institutional AI gateway deployed within AI chat agents such as ChatGPT and Claude, connecting students to multi-publisher scholarly content via secure MCP integration; early access program launched July 2026 Web of Science Research Intelligence transforms AI from a search tool into a trusted decision-making layer for research workflows, marking a shift from bibliometrics to institutional intelligence and raising the stakes for Elsevier, Digital Science, and the broader analytics market “ ” - Kate Worlock, VP & Lead Analyst1 1 Outsell, Inc., a California-based research and advisory firm for data, information & analytics; https://outsellinc.com/

Driving AI Innovation Momentum Across The IP Ecosystem © 2026 Clarivate. All rights reserved. 9 Intellectual Property: IPOne AI RESEARCH ASSISTANTS AND WORKFLOW AGENTS Unified Platform for AI-Powered IP Intelligence Announced development of IPOne, combining purpose-built AI agents with trusted CompuMark, Derwent and Darts-ip proprietary data; developing in close collaboration with leading corporate IP teams and law firms AI WORKFLOW AGENTS Award-Winning AI Innovation in Trademark Intelligence RiskMark named Best AI Tool for Lawyers at the 2026 CODiE Awards, recognizing its combination of predictive and generative AI to reduce trademark risk assessment from hours to minutes IPOne1 1 Illustrative only. The 2026 Product Winners exemplify the innovation, creativity, and excellence that have defined this program for four decades. These organizations are solving complex challenges, advancing technology, and delivering solutions that make a measurable difference for their customers and industries “ ” - Jennifer Baranowski, President of the CODiE Awards

Poised To Accelerate IP Organic Growth Under Proven Leadership © 2026 Clarivate. All rights reserved. 10 Intellectual Property 1 2025A. 2 2010 to 2019. Simon Webster IP President Joined Clarivate as President of IP segment in June 2026 Former CEO of CPA Global; a prior Clarivate acquisition (October 2020), which represents ~70% of IP segment total revenue1 Achieved mid-single-digit organic CAGR during his tenure at CPA Global2 Industry veteran, brings over two decades of proven leadership across the Global IP ecosystem CLEAR LEVERS FOR ACCELERATION Focused Agenda to Drive Organic Growth Sharpening customer focus and retention across annuities and software, increasing commercial intensity in priority segments, and an accelerating innovation pipeline led by IPOne, leveraging proprietary assets STRUCTURAL STRENGTHS Scale, Proprietary Assets and Customer Trust Re-occurring annuities and renewals engine, vast collection of proprietary assets, and deep relationships with majority of the world's leading law firms and blue-chip corporate IP teams

LS&H Transaction Expected to Strengthen Financial Profile and Sharpen Strategic Focus © 2026 Clarivate. All rights reserved. 11 Life Science & Healthcare Divestment SHAREHOLDER VALUE CREATION Transaction Delivered at a Highly Accretive Multiple Values LS&H at 10x 2026E Adjusted EBITDA less capex, a 3 turn premium to Clarivate's implied valuation on the same metric as of 6/30 INCREASES RECURRING REVENUE MIX Shifting to a Higher-Quality Revenue Base Pro forma recurring revenue mix increases from 89% to ~92%, improving predictability, retention and cash flow visibility FURTHER STRENGTHENING BALANCE SHEET Applying Net Proceeds to Debt Paydown Net proceeds directed to accelerated debt paydown; combined with FCF, enables full retirement of notes by maturities in 2028 and 2029 OPERATIONAL FOCUS Streamlined Operating Model Creates more focus on scaled A&G and IP segments, enabling a simplified structure and targeted investments in organic growth

Positioned to Accelerate Organic Growth © 2026 Clarivate. All rights reserved. 12 We are more confident than ever in our ability to accelerate organic growth to create shareholder value VCP Building Blocks in Place, Clear Runway to Drive Growth 1 2024A vs. 2026 current indication including LS&H transaction impact. 2 Organic subscription + Re-occurring order types. 3 2024A vs. 2025A. 4 2025-26. 5 Expected to close by end of 2026, subject to customary regulatory approvals and closing conditions. ▲ 92% 1,200 bps increase in recurring mix1,2 ▲ 19 Major product & AI-powered capabilities released or in development4 ▲ 3 Disposals announced; 2 completed ● ~10X Segment EBITDA – Capex5 ▲ Expect > 100 bps sequential improvement in recurring organic growth in H2 2026 and continued momentum in 2027 BUSINESS MODEL OPTIMIZATION STRENGTHENED GO-TO-MARKET ACCELERATED AI INNOVATION RATIONALIZED PORTFOLIO ▲ 90 bps Increase in 2025 organic ACV growth3 LS&H DIVESTITURE ▼ ~0.5B Clear path to retire 2028/29 notes with FCF and LS&H net proceeds ACCELERATING DEBT PAYDOWN ACCELERATING ORGANIC GROWTH ImminentCompleted

Jonathan Collins Chief Financial Officer Financial Review

Q2 & H1 2026 Financial Results 14 Changes from Prior Year 1 See the Appendix for a reconciliation of GAAP to Non-GAAP measures. Note: Amounts in table may not sum due to rounding. $m except per share data Q2 ‘26 Q2 ‘25 Change H1 ‘26 H1 ‘25 Change Revenues $587 $621 $(34) $1,173 $1,215 $(42) Operating Expenses 787 614 173 1,343 1,229 114 Income / (Loss) from Operations $(200) $7 $(207) $(170) $(14) $(156) Interest Expense, Net 60 67 (6) 119 131 (12) Income Tax Expense (Benefit) 8 12 (4) 19 31 (12) Net Income / (Loss) $(269) $(72) $(197) $(309) $(176) $(133) Net Income / (Loss) Per Share, basic $(0.42) $(0.11) $(0.31) $(0.48) $(0.26) $(0.22) Adjusted EBITDA1 247 262 (14) 488 495 (6) Adjusted EBITDA Margin1 42.1% 42.1% - bps 41.6% 40.7% 90 bps Adjusted Diluted EPS1 $0.19 $0.18 $0.01 $0.38 $0.32 $0.06 Operating Cash Flow $99 $116 $(17) $233 $288 $(54) Capital Spending 55 66 (11) 111 127 (16) Free Cash Flow1 44 50 (6) 123 161 (38) Revenues • Change primarily due to inorganic disposals Net Income / Loss • Loss and change over prior year due entirely to non-cash goodwill impairment charge associated with LS&H divestiture Operating Cash Flow • Change primarily due to lower Adjusted EBITDA as lower interest offset by higher working capital requirements © 2026 Clarivate. All rights reserved.

Changes from Prior Year Q2 2026 Revenues and Adj. EBITDA1 151 See the Appendix for a reconciliation of GAAP to Non-GAAP measures. Note: Amounts in table may not sum due to rounding. Q2 2025 Q2 2026 $621 $587 $262 42.1% $247 42.1% Revenues Adj. EBITDA1 Year + Better - Worse $ millions ($1) ($7) ($9) ($1) ($24) ($7) Organic • Continued growth in recurring revenues and strong cost discipline largely mitigated profit impact from lower transactional revenues Inorganic Disposals • Impact from A&G and LS&H disposals Foreign Exchange • Strengthening of a basket of foreign currencies versus USD drove translation impact © 2026 Clarivate. All rights reserved. FXOrganic Inorganic Disposals Inorganic Divestitures Recurring ~+3 Transactional ~(11)

Changes from Prior Year H1 2026 Revenues and Adj. EBITDA1 161 See the Appendix for a reconciliation of GAAP to Non-GAAP measures. 2 Subscription Revenues + Re-occurring Revenues. Note: Amounts in table may not sum due to rounding. H1 2025 H1 2026 $1,215 $1,173 $495 40.7% $488 41.6% Revenues Adj. EBITDA1 Year + Better - Worse $ millions $12 ($5) $8 ($49) ($10) Organic • Continued growth in recurring revenues and strong cost discipline more than offset lower transactional revenues Inorganic Disposals • Impact from A&G and LS&H disposals Foreign Exchange • Strengthening of a basket of foreign currencies versus USD drove translation impact as well as transaction gains last year that did not recur this year © 2026 Clarivate. All rights reserved. FXOrganic Inorganic Disposals Inorganic Divestitures Recurring2 ~+7 ($5) Transactional ~(12)

Q2 & H1 2026 Cash Flow 17 Changes from Prior Year $m Q2 ‘26 Q2 ‘25 Change H1 ‘26 H1 ‘25 Change Adj. EBITDA1 $247 $262 $(14) $488 $495 $(6) One-Time Costs2 (16) (18) 3 (34) (42) 8 Interest (77) (92) 15 (117) (126) 9 Taxes (19) (17) (2) (27) (24) (3) Working Capital (34) (10) (24) (71) (1) (70) Other3 (2) (7) 5 (6) (15) 9 Operating Cash Flow 99 116 (17) 233 288 (54) Capital Spending (55) (66) 11 (111) (127) 16 Free Cash Flow1 $44 $50 $(6) $123 $161 $(38) Debt Repayment (72) - (72) (211) - (211) Share Repurchase - (50) 50 (18) (100) 82 Acquisitions / Divestitures 5 6 (1) 5 6 (1) Other4 (2) 3 (5) (11) - (11) Cash Flow $(25) $9 $(34) $(112) $67 $(179) Free Cash Flow1 • Change from prior year driven entirely by working capital, largely due to timing of collections and disbursements as well as higher incentive compensation payout Capital Allocation • Repurchased $75m face value of 2028 bonds in the open market at a discount of ~3% • Achieved efficiencies enabling lower operating cash balance 1 See the Appendix for a reconciliation of GAAP to Non-GAAP measures. 2 Includes restructuring-related severance and transaction cost. 3 Includes impaired contractual costs. 4 Fx, Tax withholding for share-based compensation and refinancing cost. Note: Amounts in table may not sum due to rounding. © 2026 Clarivate. All rights reserved.

FY 2026 Guidance Reaffirmed; Assumes LS&H Divestiture Closes at Year End5 18 ACV Organic Growth • Likely in lower half of range as LS&H moves to discontinued ops in H2 Recurring Organic Growth • Subscription growth acceleration and stable re-occurring revenues Revenues Incl. Discontinued Ops • Decline over prior year due entirely to strategic disposals; revenue mix likely above original range as LS&H moves to discontinued ops in H2 Adj. EBITDA / Margin / Adj. EPS1 • Margin expansion driven by organic growth and cost discipline • EPS growth due to share repurchases Free Cash Flow1 • At low end of range due to ~$20m of one-time costs to close transaction and ~$10m to achieve cost savings +50 bps ACV Organic Growth 2% 3% ~2¼% Recurring Organic Revenue Mix3 88% 90% ~92% +400 bps Adj. EBITDA1 $980m $1,040m ~$1,005m ~Flat Adj. EBITDA Margin1 42% 43½% ~42¾% +200 bps Adj. Diluted EPS1 80₵70₵ ~75₵ +9% Free Cash Flow1 $365m $435m ~$365m ~Flat (4)% Revenues Including Discontinued Ops1 $2,300m $2,420m ~$2,350m +90 bps Recurring Organic Growth2 ¾% 2¼% ~1½% Current vs. PY 1 See the Appendix for a reconciliation of GAAP to Non-GAAP measures. 2 Subscription + Re-occurring order types. 3 (Subscription + Re-occurring) / Total Revenues excluding disposals. 4 Mid Point included for illustrative purposes only. 5 Closing of LS&H divestiture is subject to customary regulatory approvals and closing conditions. Mid Point4Guidance Range Current Indication © 2026 Clarivate. All rights reserved. Extended Guidance Range

FY 2026 Revenues and Adj. EBITDA1 Outlook 19 2025A 2026T $2,455 ~$2,350 $1,002 40.8% ~$1,005 ~42.8% Revenues Adj. EBITDA1 Year + Better - Worse FXOrganic ~$25 Inorganic Disposals ~($125) ~($25) Changes from Prior Year ($ millions) Inorganic Divestitures 1 See the Appendix for a reconciliation of GAAP to Non-GAAP measures. Note: Amounts in table may not sum due to rounding. ~$20 Organic • Recurring revenue growth partially offset by modest transactional decline • Strong profit flow-through driven by disciplined cost management Inorganic Disposals • Books transactional revenues gone by mid-year, RWD by end of year Inorganic Divestitures • Guidance does not include potential sale of LS&H business Foreign Exchange • Expect modest benefit associated with weaker USD © 2026 Clarivate. All rights reserved.

41.5% 39.3% 42.1% 40.5% 41.3% 41.2% 42.1% FY 2026 Quarterly Phasing 20 Revenue, Organic ACV Growth, Organic Recurring Revenue Growth and Adj. EBITDA % Revenues Incl. Discontinued Ops • Less seasonality this year due to increased recurring revenue mix because of the disposals Organic ACV • Expect acceleration through the balance of the year from momentum of new subs sales Organic Recurring Revenue • Experienced slight sequential pull back in Q2 due to timing of subs renewals; expected to accelerate in H2 from return to growth in re- occurring revenues and subs growth acceleration Adj. EBITDA Margin1 • Expect acceleration through the balance of the year from organic growth conversion and disposals Revenue ($M) FY 2025AFY 2024A Adj. EBITDA Margin (%)1 2024A revenue represents quarterly average revenue for the year. 1 See the Appendix for a reconciliation of GAAP to Non-GAAP measures. © 2026 Clarivate. All rights reserved. 500 520 540 560 580 600 620 640 660 H2 2026EH1 2026A 0.9% 1.2% 1.3% 1.6% 1.8% 1.6% 1.5% 0.1% 0.6% 0.8% 0.3% 0.5% 1.0% 0.5% 2024A Q1 25A Q2 25A Q3 25A Q4 25A Q1 26A Q2 26A Q3 26E Q4 26E Organic ACV Growth (%) Organic Recurring Revenue Growth (%)

FY 2026 Cash Flow Outlook 21 Changes from Prior Year ($ millions) Free Cash Flow1 • Expecting flat versus prior year due to higher one-time transaction related costs from LS&H divestiture Capital Allocation • Redeemed $100m of 2026 notes and repurchased $43m of 2028 and 2029 notes in Q1 • Repurchased another $75m of 2028 notes in Q2 • Plan to utilize FCF to retire ~$200m of 2028 notes in H2 • Plan to use net proceeds from LS&H divestiture, which is expected to close before year end, to retire an additional ~$500m of the 2028 and 2029 notes 1 See the Appendix for a reconciliation of GAAP to Non-GAAP measures. 2 Includes restructuring-related severance and transaction cost. 3 Includes impaired contractual costs. 4 Fx, tax withholding for share-based compensation, and refinancing cost. Note: Amounts in table may not sum due to rounding. 2026 Outlook 2025 Actuals Change Adj. EBITDA1 ~$1,005 $1,002 ~Flat One-Time Costs2 ~(70) (67) ~(5) Interest ~(235) (253) ~20 Taxes ~(50) (42) ~(10) Working Capital ~(25) 12 ~(35) Other3 ~(15) (23) ~10 Operating Cash Flow ~610 629 ~(20) Capital Spending ~(245) (263) ~20 Free Cash Flow1 ~$365 $365 ~Flat Debt Repayment ~(900) (100) ~(800) Share Repurchase ~(20) (225) ~205 Acquisitions / Divestitures ~495 3 ~490 Other4 ~(15) (9) ~(5) Cash Flow ~$(75) $34 ~$(110) © 2026 Clarivate. All rights reserved.

CFO Leadership Transition © 2026 Clarivate. All rights reserved. 22 Michael Easton Appointed EVP & CFO Experienced, proven leader brings more than 25 years of financial and operational expertise Appointment underscores depth and strength of leadership bench, enabling seamless transition Focus will be on accelerating growth, improving profitability, strengthening FCF generation and maintaining disciplined capital allocation Previously oversaw corporate FP&A, product and global finance teams at IHS Inc.; subsequently led global accounting, financial reporting and operations at IHS Markit Ltd. following merger with Markit Ltd.

Q&A Session

Appendix Presentation of Certain Non-GAAP Financial Measures

25© 2026 Clarivate. All rights reserved. Presentation of Certain Non-GAAP Financial Measures Adjusted EBITDA and Adjusted EBITDA margin Adjusted EBITDA represents net income (loss) before the provision (benefit) for income taxes, depreciation and amortization, and interest expense, net, adjusted to exclude share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign currency gains/losses, legal settlements, and other items that are included in net income (loss) for the period that we do not consider indicative of our ongoing operating performance. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA by Revenues. Net income (loss) margin is calculated by dividing Net income (loss) by Revenues. Adjusted net income and Adjusted diluted EPS Adjusted net income represents net income (loss), adjusted to exclude amortization related to acquired intangible assets, share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign currency gains/losses, legal settlements, and other items that are included in net income (loss) for the period that we do not consider indicative of our ongoing operating performance and the associated income tax impact of such adjustments. Adjusted diluted EPS is calculated by dividing Adjusted net income by Adjusted diluted weighted average shares. The adjusted diluted weighted average shares calculation assumes that all instruments in the calculation are dilutive. Free cash flow Free cash flow represents Net cash provided by (used for) operating activities less capital expenditures. Revenues, including discontinued operations Revenues, including discontinued operations represents total company revenues including those attributable to discontinued operations, which will begin to be reported in the third quarter for the LS&H segment.

26 $m Q2 ‘26 Q2 ’25 H1 ’26 H1 ’25 Net income (loss) $(268.6) $(72.0) $(308.8) $(175.9) Provision (benefit) for income taxes 8.0 12.3 19.4 31.1 Depreciation and amortization 185.7 190.9 369.7 376.3 Interest expense, net 60.4 66.6 119.4 130.9 Share-based compensation expense 15.1 18.5 29.7 29.6 Goodwill and intangible asset impairments 221.7 — 221.7 — Restructuring costs 12.1 9.3 24.1 34.0 Transaction related costs 10.2 8.1 18.4 14.4 Other1 2.6 27.9 (5.2) 54.4 Adjusted EBITDA $247.2 $261.6 $488.4 $494.8 Net income (loss) margin (45.7)% (11.6)% (26.3)% (14.5)% Adjusted EBITDA margin 42.1% 42.1% 41.6% 40.7% © 2026 Clarivate. All rights reserved. 1 Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing operating performance. Reconciliation of Non-GAAP Financial Measures Net income (loss) to Adjusted EBITDA and Adjusted EBITDA margin

Reconciliation of Non-GAAP Financial Measures 27 Net income (loss) and Net income (loss) per share to Adjusted net income and Adjusted diluted EPS © 2026 Clarivate. All rights reserved. 1 Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing operating performance. Q2 ‘26 Q2 ‘25 H1 ’26 H1 ‘25 $m except per share data Amount Per Share Amount Per Share Amount Per Share Amount Per Share Net income (loss) and Diluted EPS $(268.6) $(0.42) $(72.0) $(0.11) $(308.8) $(0.48) $(175.9) $(0.26) Amortization related to acquired intangible assets 135.3 0.21 137.0 0.20 270.7 0.42 273.3 0.40 Share-based compensation expense 15.1 0.02 18.5 0.03 29.7 0.05 29.6 0.04 Goodwill and intangible asset impairments 221.7 0.35 — — 221.7 0.35 — — Restructuring costs 12.1 0.02 9.3 0.01 24.1 0.04 34.0 0.05 Transaction related costs 10.2 0.02 8.1 0.01 18.4 0.03 14.4 0.02 Other1 4.3 — 28.0 0.05 (1.9) (0.01) 54.5 0.09 Income tax impact of related adjustments (7.0) (0.01) (5.6) (0.01) (11.5) (0.02) (10.8) (0.02) Adjusted net income and Adjusted diluted EPS $123.1 $0.19 $123.3 $0.18 $242.4 $0.38 $219.1 $0.32 Adjusted weighted average ordinary shares, diluted 642.7 684.6 645.0 689.9

28© 2026 Clarivate. All rights reserved. $m Q2 ‘26 Q2 ‘25 H1 ’26 H1 ’25 Net cash provided by operating activities $98.7 $116.3 $233.4 $287.5 Capital expenditures (54.7) (66.0) (110.5) (126.9) Free cash flow $44.0 $50.3 $122.9 $160.6 Reconciliation of Non-GAAP Financial Measures Net cash provided by operating activities to Free cash flow

29© 2026 Clarivate. All rights reserved. Year Ending December 31, 2026 (Forecasted) Year Ended December 31, $m Low High 2025 Net income (loss) $(418) $(353) $(201.1) Provision (benefit) for income taxes 45 45 7.2 Depreciation and amortization 760 760 757.2 Interest expense, net 242 237 265.4 Share-based compensation expense 70 70 63.0 Goodwill and intangible asset impairments 222 222 15.0 Restructuring costs1 35 35 50.7 Transaction related costs 35 35 22.5 Other (11) (11) 21.9 Adjusted EBITDA $980 $1,040 $1,001.8 Net income (loss) margin (18.2)% (14.6)% (8.2)% Adjusted EBITDA margin 42.0% 43.5% 40.8% 1 For the 2026 outlook, reflects restructuring costs expected to be incurred associated with the Value Creation Plan. Reconciliation of Non-GAAP Financial Measures – 2026 Outlook Net income (loss) to Adjusted EBITDA and Adjusted EBITDA margin

30© 2026 Clarivate. All rights reserved. Year Ending December 31, 2026 (Forecasted) Low High Net income (loss) per share $(0.64) $(0.54) Amortization related to acquired intangible assets 0.83 0.83 Share-based compensation expense 0.11 0.11 Goodwill and intangible asset impairments 0.34 0.34 Restructuring costs1 0.05 0.05 Transaction related costs 0.05 0.05 Other (0.01) (0.01) Income tax impact of related adjustments (0.03) (0.03) Adjusted diluted EPS $0.70 $0.80 Adjusted weighted average ordinary shares, diluted ~650 million Reconciliation of Non-GAAP Financial Measures – 2026 Outlook 1 Reflects restructuring costs expected to be incurred in 2026 associated with the Value Creation Plan. Net income (loss) per fully diluted weighted shares outstanding to Adjusted diluted EPS

31 Year Ending December 31, 2026 (Forecasted) Year Ended December 31, $m Low High 2025 Net cash provided by operating activities $610 $680 $628.5 Capital expenditures (245) (245) (263.2) Free cash flow $365 $435 $365.3 © 2026 Clarivate. All rights reserved. Reconciliation of Non-GAAP Financial Measures – 2026 Outlook Net cash provided by operating activities to Free cash flow

32 Year Ending December 31, 2026 (Forecasted) $m Low High Revenues, including discontinued operations $2,300 $2,420 Revenues attributable to discontinued operations (360) (380) Revenues $1,940 $2,040 © 2026 Clarivate. All rights reserved. Revenues, including discontinued operations to Revenues Reconciliation of Non-GAAP Financial Measures – 2026 Outlook

© 2026 Clarivate Clarivate and its logo, as well as all other trademarks used herein, are trademarks of their respective owners and used under license. About Clarivate Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

GRAPHIC

Filename: ex992q22026supplementald001.jpg · Sequence: 7

Binary file (142879 bytes)

Download ex992q22026supplementald001.jpg

GRAPHIC

Filename: ex992q22026supplementald002.jpg · Sequence: 8

Binary file (280227 bytes)

Download ex992q22026supplementald002.jpg

GRAPHIC

Filename: ex992q22026supplementald003.jpg · Sequence: 9

Binary file (237474 bytes)

Download ex992q22026supplementald003.jpg

GRAPHIC

Filename: ex992q22026supplementald004.jpg · Sequence: 10

Binary file (35082 bytes)

Download ex992q22026supplementald004.jpg

GRAPHIC

Filename: ex992q22026supplementald005.jpg · Sequence: 11

Binary file (46556 bytes)

Download ex992q22026supplementald005.jpg

GRAPHIC

Filename: ex992q22026supplementald006.jpg · Sequence: 12

Binary file (107385 bytes)

Download ex992q22026supplementald006.jpg

GRAPHIC

Filename: ex992q22026supplementald007.jpg · Sequence: 13

Binary file (99209 bytes)

Download ex992q22026supplementald007.jpg

GRAPHIC

Filename: ex992q22026supplementald008.jpg · Sequence: 14

Binary file (131148 bytes)

Download ex992q22026supplementald008.jpg

GRAPHIC

Filename: ex992q22026supplementald009.jpg · Sequence: 15

Binary file (115967 bytes)

Download ex992q22026supplementald009.jpg

GRAPHIC

Filename: ex992q22026supplementald010.jpg · Sequence: 16

Binary file (118132 bytes)

Download ex992q22026supplementald010.jpg

GRAPHIC

Filename: ex992q22026supplementald011.jpg · Sequence: 17

Binary file (104174 bytes)

Download ex992q22026supplementald011.jpg

GRAPHIC

Filename: ex992q22026supplementald012.jpg · Sequence: 18

Binary file (102168 bytes)

Download ex992q22026supplementald012.jpg

GRAPHIC

Filename: ex992q22026supplementald013.jpg · Sequence: 19

Binary file (46386 bytes)

Download ex992q22026supplementald013.jpg

GRAPHIC

Filename: ex992q22026supplementald014.jpg · Sequence: 20

Binary file (115517 bytes)

Download ex992q22026supplementald014.jpg

GRAPHIC

Filename: ex992q22026supplementald015.jpg · Sequence: 21

Binary file (107051 bytes)

Download ex992q22026supplementald015.jpg

GRAPHIC

Filename: ex992q22026supplementald016.jpg · Sequence: 22

Binary file (113127 bytes)

Download ex992q22026supplementald016.jpg

GRAPHIC

Filename: ex992q22026supplementald017.jpg · Sequence: 23

Binary file (119405 bytes)

Download ex992q22026supplementald017.jpg

GRAPHIC

Filename: ex992q22026supplementald018.jpg · Sequence: 24

Binary file (140087 bytes)

Download ex992q22026supplementald018.jpg

GRAPHIC

Filename: ex992q22026supplementald019.jpg · Sequence: 25

Binary file (116967 bytes)

Download ex992q22026supplementald019.jpg

GRAPHIC

Filename: ex992q22026supplementald020.jpg · Sequence: 26

Binary file (120323 bytes)

Download ex992q22026supplementald020.jpg

GRAPHIC

Filename: ex992q22026supplementald021.jpg · Sequence: 27

Binary file (120639 bytes)

Download ex992q22026supplementald021.jpg

GRAPHIC

Filename: ex992q22026supplementald022.jpg · Sequence: 28

Binary file (86686 bytes)

Download ex992q22026supplementald022.jpg

GRAPHIC

Filename: ex992q22026supplementald023.jpg · Sequence: 29

Binary file (25258 bytes)

Download ex992q22026supplementald023.jpg

GRAPHIC

Filename: ex992q22026supplementald024.jpg · Sequence: 30

Binary file (36930 bytes)

Download ex992q22026supplementald024.jpg

GRAPHIC

Filename: ex992q22026supplementald025.jpg · Sequence: 31

Binary file (122821 bytes)

Download ex992q22026supplementald025.jpg

GRAPHIC

Filename: ex992q22026supplementald026.jpg · Sequence: 32

Binary file (90015 bytes)

Download ex992q22026supplementald026.jpg

GRAPHIC

Filename: ex992q22026supplementald027.jpg · Sequence: 33

Binary file (112909 bytes)

Download ex992q22026supplementald027.jpg

GRAPHIC

Filename: ex992q22026supplementald028.jpg · Sequence: 34

Binary file (53833 bytes)

Download ex992q22026supplementald028.jpg

GRAPHIC

Filename: ex992q22026supplementald029.jpg · Sequence: 35

Binary file (87326 bytes)

Download ex992q22026supplementald029.jpg

GRAPHIC

Filename: ex992q22026supplementald030.jpg · Sequence: 36

Binary file (81565 bytes)

Download ex992q22026supplementald030.jpg

GRAPHIC

Filename: ex992q22026supplementald031.jpg · Sequence: 37

Binary file (57088 bytes)

Download ex992q22026supplementald031.jpg

GRAPHIC

Filename: ex992q22026supplementald032.jpg · Sequence: 38

Binary file (55248 bytes)

Download ex992q22026supplementald032.jpg

GRAPHIC

Filename: ex992q22026supplementald033.jpg · Sequence: 39

Binary file (111587 bytes)

Download ex992q22026supplementald033.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 41

v3.26.1

Document and Entity Information Document

Jul. 29, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Jul. 29, 2026

Entity Registrant Name

CLARIVATE PLC

Entity Incorporation, State or Country Code

Entity File Number

001-38911

Entity Tax Identification Number

00-0000000

Entity Address, Address Line One

70 St. Mary Axe

Entity Address, City or Town

London

Entity Address, Postal Zip Code

EC3A 8BE

Entity Address, Country

City Area Code

Local Phone Number

207-433-4000

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Ordinary Shares, no par value

Trading Symbol

CLVT

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Entity Central Index Key

0001764046

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration